![](/img/cover-not-exists.png)
Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors
Rodon, Jordi, Braña, Irene, Siu, Lillian L, Jonge, Maja J, Homji, Natasha, Mills, David, Tomaso, Emmanuelle, Sarr, Celine, Trandafir, Lucia, Massacesi, Cristian, Eskens, Ferry, Bendell, Johanna CVolume:
32
Language:
english
Journal:
Investigational New Drugs
DOI:
10.1007/s10637-014-0082-9
Date:
August, 2014
File:
PDF, 925 KB
english, 2014